Cliff Asness's LLY Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 506,839 shares of Eli Lilly and Company (LLY) worth $544.69 M, representing 0.29% of the portfolio. First purchased in 2012-Q4, this long-term strategic position has been held for 53 quarters.
Based on 13F filings since 2013, Cliff Asness has maintained a long-term strategic position in LLY, representing a significant commitment to this investment thesis. Largest addition occurred in Q4 2018, adding 1.59 M shares. Largest reduction occurred in Q3 2019, reducing 1.45 M shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's Eli Lilly and Company (LLY) Holding Value Over Time
Track share changes against reported price movement
Quarterly Eli Lilly and Company (LLY) Trades by Cliff Asness
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +55,657 | Add 12.34% | 506,839 | $1074.68 |
| Q3 2025 | +104,207 | Add 30.03% | 451,182 | $733.24 |
| Q2 2025 | -220,528 | Reduce 38.86% | 346,975 | $777.14 |
| Q1 2025 | -76,441 | Reduce 11.87% | 567,503 | $803.79 |
| Q4 2024 | -33,693 | Reduce 4.97% | 643,944 | $770.51 |
| Q3 2024 | +203,085 | Add 42.80% | 677,637 | $873.31 |
| Q2 2024 | +70,122 | Add 17.34% | 474,552 | $905.38 |
| Q1 2024 | +68,495 | Add 20.39% | 404,430 | $777.96 |
| Q4 2023 | +30,302 | Add 9.91% | 335,935 | $582.92 |
| Q3 2023 | +1,448 | Add 0.48% | 305,633 | $537.13 |
| Q2 2023 | -27,007 | Reduce 8.15% | 304,185 | $466.71 |
| Q1 2023 | -45,133 | Reduce 11.99% | 331,192 | $343.11 |
| Q4 2022 | -106,760 | Reduce 22.10% | 376,325 | $365.84 |
| Q3 2022 | -55,251 | Reduce 10.26% | 483,085 | $323.35 |
| Q2 2022 | -331,785 | Reduce 38.13% | 538,336 | $323.10 |
| Q1 2022 | -107,175 | Reduce 10.97% | 870,121 | $286.37 |
| Q4 2021 | +77,648 | Add 8.63% | 977,296 | $276.22 |
| Q3 2021 | -53,712 | Reduce 5.63% | 899,648 | $231.05 |
| Q2 2021 | -117,454 | Reduce 10.97% | 953,360 | $229.52 |
| Q1 2021 | -369,380 | Reduce 25.65% | 1.07 M | $185.38 |
| Q4 2020 | -66,733 | Reduce 4.43% | 1.44 M | $166.99 |
| Q3 2020 | +169,421 | Add 12.67% | 1.51 M | $145.68 |
| Q2 2020 | -131,280 | Reduce 8.94% | 1.34 M | $162.69 |
| Q1 2020 | -1.05 M | Reduce 41.69% | 1.47 M | $135.23 |
| Q4 2019 | -369,787 | Reduce 12.80% | 2.52 M | $130.78 |
| Q3 2019 | -1.45 M | Reduce 33.37% | 2.89 M | $111.83 |
| Q2 2019 | +1.51 M | Add 53.28% | 4.34 M | $110.72 |
| Q1 2019 | -782,294 | Reduce 21.66% | 2.83 M | $129.55 |
| Q4 2018 | +1.59 M | Add 78.88% | 3.61 M | $115.72 |
| Q3 2018 | +951,817 | Add 89.22% | 2.02 M | $107.31 |
| Q2 2018 | -637,563 | Reduce 37.41% | 1.07 M | $85.33 |
| Q1 2018 | -346,580 | Reduce 16.90% | 1.7 M | $77.37 |
| Q4 2017 | +158,755 | Add 8.39% | 2.05 M | $84.46 |
| Q3 2017 | +284,380 | Add 17.69% | 1.89 M | $85.54 |
| Q2 2017 | +365,539 | Add 29.42% | 1.61 M | $82.30 |
| Q1 2017 | -246,535 | Reduce 16.56% | 1.24 M | $84.11 |
| Q4 2016 | +30,655 | Add 2.10% | 1.49 M | $73.55 |
| Q3 2016 | +124,873 | Add 9.37% | 1.46 M | $80.26 |
| Q2 2016 | -580,360 | Reduce 30.33% | 1.33 M | $78.75 |
| Q1 2016 | -446,807 | Reduce 18.93% | 1.91 M | $72.01 |
| Q4 2015 | -78,844 | Reduce 3.23% | 2.36 M | $84.26 |
| Q3 2015 | +451,787 | Add 22.73% | 2.44 M | $83.69 |
| Q2 2015 | -349,718 | Reduce 14.96% | 1.99 M | $83.49 |
| Q1 2015 | +269,239 | Add 13.02% | 2.34 M | $72.65 |
| Q4 2014 | +610,321 | Add 41.87% | 2.07 M | $68.99 |
| Q3 2014 | -461,233 | Reduce 24.04% | 1.46 M | $64.85 |
| Q2 2014 | -295,500 | Reduce 13.34% | 1.92 M | $62.17 |
| Q1 2014 | -1.14 M | Reduce 33.99% | 2.21 M | $58.86 |
| Q4 2013 | +40,998 | Add 1.24% | 3.35 M | $51.00 |
| Q3 2013 | -564,803 | Reduce 14.56% | 3.31 M | $50.33 |
| Q2 2013 | +3.88 M | Add 0.00% | 3.88 M | $49.12 |
| Q4 2012 | +2.8 M | Add 0.00% | 2.8 M | $49.32 |
Cliff Asness's Eli Lilly and Company Investment FAQs
Cliff Asness first purchased Eli Lilly and Company (LLY) in Q4 2012, acquiring 2,802,050 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held Eli Lilly and Company (LLY) for 53 quarters since Q4 2012.
Cliff Asness's largest addition to Eli Lilly and Company (LLY) was in Q2 2013, adding 3,878,291 shares worth $190.5 M.
According to the latest 13F filing for Q4 2025, Cliff Asness's firm, Aqr Capital Management LLC, owns 506,839 shares of Eli Lilly and Company (LLY), valued at approximately $544.69 M.
As of the Q4 2025 filing, Eli Lilly and Company (LLY) represents approximately 0.29% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings.
Cliff Asness's peak holding in Eli Lilly and Company (LLY) was 4,335,702 shares, as reported at the end of Q2 2019.